The Financial Times has an article on the U.S. Supreme Court’s decision to grant cert in the Dura Pharmaceuticals case and address the issue of loss causation. The article also discusses the potential impact on the research analyst cases.
Quote of note: “The Supreme Court is not expected to rule on the Dura case until 2005; an appeal in the Merrill Lynch case is due to begin in New York next month, although some lawyers believe that ruling may be put off until after the Supreme Court acts.”
Disclosure: The author of The 10b-5 Daily is quoted in the article.
The 10b-5 Daily 